Skip to main navigation
ANI Pharmaceuticals, Inc.
  • About
    Executive Team Board of Directors
    How We Operate
    Quality Capabilities
    Locations News
  • Products
  • Contract Manufacturing
  • Investors
  • We're Hiring
    We're Hiring Career Benefits Job Openings Open Commercial Positions Employment Application Where We Live
  • Contact
    Contact Us Locations

News

Investors Menu
  • Overview
  • News
  • Events & Presentations
  • Stock Information
    Stock Quote & Chart Investment Calculator Analyst Coverage
  • Financials
    Quarterly Results Annual Reports SEC Filings
  • Governance
    Governance Documents Executive Management Board of Directors Committee Composition
  • Resources
    Investor FAQs Information Request Form Investor Email Alerts Investor Contacts
04/24/2023
ANI Pharmaceuticals Announces the FDA Approval and Launch of Nitrofurantoin Oral Suspension USP
04/04/2023
ANI Pharmaceuticals Announces the FDA Approval of Colestipol Hydrochloride Tablets USP
03/09/2023
ANI Pharmaceuticals Reports Record Fourth Quarter Financial Results and Achieves Full Year 2022 Revenue Milestone; Initiates 2023 Guidance
02/22/2023
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2022 Financial Results on March 9, 2023, at 8:30 a.m. ET

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Page 2
  • Current page 3
Displaying 21 - 24 of 24

Contact Us

INVESTOR CONTACT

In-Site Communications, Inc.
Lisa M. Wilson

212-452-2793
envelope iconIR@anipharmaceuticals.com

Quick Links

  • SEC Filings
  • Investor FAQs
  • Information Request Form
Unsubscribe
ANI Pharmaceuticals, Inc.
Products | Investors | Careers | Contact Us | Privacy Policy | Terms of Use | Accessibility
© Copyright 2023 ANI Pharmaceuticals, Inc.
Linkedin Youtube